trending Market Intelligence /marketintelligence/en/news-insights/trending/3EoHMNlkdmkt-a3d_8q57A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biotechnology company Cabaletta Bio plans $77.5M Nasdaq IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Biotechnology company Cabaletta Bio plans $77.5M Nasdaq IPO

Cabaletta Bio Inc. is planning an IPO to list 5.8 million of its shares on the Nasdaq Global Market under the ticker CABA.

The Philadelphia-based clinical-stage biotechnology company expects to price its common shares between $14 and $16 apiece and raise net proceeds of about $77.5 million, if each share is priced at $15.

Cabaletta Bio has granted the underwriters an option to buy up to an additional 870,000 shares at the public offering price.

Assuming a per-share price of $15, the net proceeds from the offering would be $89.6 million if the underwriters fully exercise their option.

The company plans to use the net proceeds primarily to further the clinical development of desmoglein 3 chimeric autoantibody receptor T cells, a potential therapy to counter a rare autoimmune disorder called mucosal pemphigus vulgaris.

The rest of the proceeds will be used for new and ongoing research and development activities as well as for working capital and other corporate purposes.

Morgan Stanley & Co. LLC, Cowen and Co. LLC and Evercore Group LLC are acting as underwriters in the IPO.